164 related articles for article (PubMed ID: 37953192)
21. Lymphoblastic Lymphoma: a Concise Review.
Intermesoli T; Weber A; Leoncin M; Frison L; Skert C; Bassan R
Curr Oncol Rep; 2022 Jan; 24(1):1-12. PubMed ID: 35059993
[TBL] [Abstract][Full Text] [Related]
22. T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
Hoelzer D; Gökbuget N
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S214-21. PubMed ID: 19778844
[TBL] [Abstract][Full Text] [Related]
23. Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma.
DiGiuseppe JA; Wood BL
Cytometry B Clin Cytom; 2019 Jul; 96(4):256-265. PubMed ID: 31231940
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of MRD monitoring based on
Arunachalam AK; Janet NB; Korula A; Lakshmi KM; Kulkarni UP; Aboobacker FN; Abraham A; George B; Balasubramanian P; Mathews V
Leuk Lymphoma; 2020 Dec; 61(14):3468-3475. PubMed ID: 32852239
[TBL] [Abstract][Full Text] [Related]
25. BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
Yenamandra AK; Kaviany S; Borinstein SC; Friedman DL; Kovach AE
Lab Med; 2019 Oct; 50(4):401-405. PubMed ID: 30938769
[TBL] [Abstract][Full Text] [Related]
26. [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
Pan Y; Li GD; Liu WP; Zhang WY; Tang Y; Li FY
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):810-5. PubMed ID: 20193455
[TBL] [Abstract][Full Text] [Related]
27. Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.
Wenzinger C; Williams E; Gru AA
Curr Hematol Malig Rep; 2018 Aug; 13(4):275-288. PubMed ID: 29951888
[TBL] [Abstract][Full Text] [Related]
28. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
[TBL] [Abstract][Full Text] [Related]
29. Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method.
Borowitz MJ; Wood BL; Keeney M; Hedley BD
Curr Protoc; 2022 Mar; 2(3):e383. PubMed ID: 35263042
[TBL] [Abstract][Full Text] [Related]
30. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
31. Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.
Leung KT; Cai J; Liu Y; Chan KYY; Shao J; Yang H; Hu Q; Xue Y; Wu X; Guo X; Zhai X; Wang N; Li X; Tian X; Li Z; Xue N; Guo Y; Wang L; Zou Y; Xiao P; He Y; Jin R; Tang J; Yang JJ; Shen S; Pui CH; Li CK
Leukemia; 2024 Feb; 38(2):250-257. PubMed ID: 38001171
[TBL] [Abstract][Full Text] [Related]
32. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
33. Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario.
Tierens A; Stockley TL; Campbell C; Fulcher J; Leber B; McCready E; Sabatini PJB; Sadikovic B; Schuh AC
Curr Oncol; 2021 Mar; 28(2):1376-1387. PubMed ID: 33808300
[TBL] [Abstract][Full Text] [Related]
34. Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia.
Bontoux C; Simonin M; Garnier N; Lhermitte L; Touzart A; Andrieu G; Bruneau J; Lengliné E; Plesa A; Boissel N; Baruchel A; Bertrand Y; Molina TJ; Macintyre E; Asnafi V
Mod Pathol; 2022 Sep; 35(9):1227-1235. PubMed ID: 35562412
[TBL] [Abstract][Full Text] [Related]
35. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
36. BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with
Takahashi T; Ichikawa S; Ichinohasama R; Harigae H
Leuk Lymphoma; 2020 May; 61(5):1265-1267. PubMed ID: 31876209
[No Abstract] [Full Text] [Related]
37. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
Zuna J; Hovorkova L; Krotka J; Koehrmann A; Bardini M; Winkowska L; Fronkova E; Alten J; Koehler R; Eckert C; Brizzolara L; Trkova M; Stuchly J; Zimmermann M; De Lorenzo P; Valsecchi MG; Conter V; Stary J; Schrappe M; Biondi A; Trka J; Zaliova M; Cazzaniga G; Cario G
Leukemia; 2022 Dec; 36(12):2793-2801. PubMed ID: 35933523
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis.
Beishuizen A; Verhoeven MA; van Wering ER; Hählen K; Hooijkaas H; van Dongen JJ
Blood; 1994 Apr; 83(8):2238-47. PubMed ID: 8161789
[TBL] [Abstract][Full Text] [Related]
39. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
[TBL] [Abstract][Full Text] [Related]
40. Mucin 4 protein is expressed in B-acute lymphoblastic leukemia and is restricted to BCR::ABL1-positive and BCR::ABL-like subtypes.
Gestrich CK; De Lancy SJ; Kresak A; Sinno MG; Yalley A; Pateva I; Meyerson H; Shetty S; Oduro KA
Hum Pathol; 2023 Jun; 136():75-83. PubMed ID: 37023866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
